Table 2.

Univariable analysis of objective response, progression-free survival and overall survival with relevant clinical and genomic characteristics

Characteristics	Objective response		Progression free Survival		Overall survival
	OR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.00 (1.00 to 1.01)	0.28	0.99 (0.97 to 1.01)	0.20	1.00 (0.98 to 1.03)	0.90
Bladder versus upper tract UC	0.89 (0.73 to 1.08)	0.23	1.03 (0.64 to 1.66)	0.91	1.47 (0.80 to 2.70)	0.22
Histology (pure UC vs mixed or pure variant histology)	1.17 (0.99 to 1.39)	0.08	0.64 (0.42 to 0.99)	0.04	0.63 (0.37 to 1.05)	0.08
Front line versus postplatinum	1.09 (0.92 to 1.28)	0.33	0.84 (0.55 to 1.27)	0.40	1.12 (0.68 to 1.83)	0.66
ECOG PS≤1	1.13 (0.92 to 1.39)	0.25	0.59 (0.35 to 1.00)	0.05	0.40 (0.22 to 0.74)	0.003
Visceral metastases	0.74 (0.62 to 0.89)	0.002	2.23 (1.32 to 3.79)	0.003	2.53 (1.29 to 4.98)	0.007
BMI	1.02 (1.00 to 1.03)	0.05	0.97 (0.93 to 1.01)	0.14	0.91 (0.86 to 0.96)	0.001
Albumin	1.20 (1.05 to 1.37)	0.009	0.57 (0.43 to 0.75)	<0.001	0.49 (0.36 to 0.67)	<0.001
Hemoglobin <100 vs ≥100 g/L	0.835 (0.70 to 1.00)	0.05	1.71 (1.11 to 2.65)	0.02	1.45 (0.85 to 2.47)	0.18
Creatinine	1.01 (0.92 to 1.11)	0.91	0.83 (0.63 to 1.08)	0.16	0.86 (0.64 to 1.16)	0.32
NLR <5 vs NLR ≥5	1.18 (1.00 to 1.40)	0.06	0.61 (0.40 to 0.94)	0.03	0.45 (0.26 to 0.75)	0.002
TMB ≥10 mut/Mb vs TMB <10 mut/Mb	3.45 (1.04 to 11.11)	0.04	0.42 (0.22 to 0.81)	0.009	0.69 (0.03 to 1.43)	0.32
TERT promoter mutation	1.33 (1.08 to 1.65)	0.01	0.41 (0.24 to 0.72)	0.002	0.53 (0.27 to 1.06)	0.07
MDM2 mutation	1.41 (1.01 to 1.96)	<0.05	0.98 (0.46 to 2.08)	0.95	0.72 (0.28 to 1.88)	0.51
CDKN2B mutation	0.94 (0.74 to 1.20)	0.61	1.36 (0.77 to 2.40)	0.29	1.91 (0.98 to 3.73)	0.06

Bold values denote statistical significance at the p < 0.05 level.

BMI, body mass index; NLR, neutrophil to lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TMB, tumor mutation burden; UC, urothelial carcinoma.